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Abstract 
 
The complement system and neutrophil granulocytes are indispensable in the immune response 
against extracellular pathogens such as bacteria and fungi. Endothelial cells also participate in antimicrobial 
immunity largely by regulating the homing of leukocytes through their cytokine production and their pattern 
of cell surface adhesion molecules. We have previously shown that mannan-binding lectin-associated serine 
protease-1 (MASP-1), a complement lectin pathway enzyme, is able to activate endothelial cells by cleaving 
protease activated receptors, which leads to cytokine production and enables neutrophil chemotaxis. 
Therefore, we aimed to investigate how recombinant MASP-1 (rMASP-1) can modify the pattern of 
P-selectin, E-selectin, ICAM-1, ICAM-2, and VCAM-1 adhesion molecules in human umbilical vein 
endothelial cells (HUVEC), and whether these changes can enhance the adherence between endothelial cells 
and neutrophil granulocyte model cells (differentiated PLB-985). We found that HUVECs activated by 
rMASP-1 decreased the expression of ICAM-2 and increased that of E-selectin, whereas ICAM-1, VCAM-1 
and P-selectin expression remained unchanged. Furthermore, these changes resulted in increased adherence 
between differentiated PLB-985 cells and endothelial cells. Our finding suggests that complement MASP-1 
can increase adhesion between neutrophils and endothelial cells in a direct fashion. This is in agreement with 
our previous finding that MASP-1 increases the production of pro-inflammatory cytokines (such as IL-6 and 
IL-8) and chemotaxis, and may thereby boost neutrophil functions. This newly described cooperation 
between complement lectin pathway and neutrophils via endothelial cells may be an effective tool to enhance 
the antimicrobial immune response. 
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1. Introduction 
 
The effectiveness of the immune system depends on the prompt and specific response against 
pathogens. Therefore, it is not surprising that immunological subsystems cooperate with one another for the 
quick recognition and elimination of invaders or altered host cells. A good example of this cooperation is the 
teamwork of the complement system and neutrophil granulocytes against bacteria and fungi. 
The complement system can be activated through different routes: the classical, the alternative, and the lectin 
pathways. After recognition of the target structure by any of the three pathways, a cascade of serine proteases 
is activated, and this leads to the cleavage of C3, the central molecule of the complement system. C3b, C4b 
and their degradation fragments act as opsonins enhancing the phagocytic activity of neutrophils (and other 
cell types). C3a and C5a are amongst the most potent chemotactic factors for neutrophils attracting them to 
the site of the infection. 
Mannan-binding lectin (MBL)-associated serine protease-1 (MASP-1) is the primary enzyme of the lectin 
pathway [1-3]. MASP-1 is activated upon the recognition of special pathogen/danger-associated motifs by 
MBL, collectin-11 (CL-K1), or ficolins (1-, 2-, and 3-ficolin) [4, 5]. Following its autoactivation, MASP-1 
cleaves MASP-2 and C2, thereby ensuring further activation of the lectin pathway. However, we and other 
groups have described several other functions of MASP-1 beyond complement activation [6]. MASP-1 can 
cleave high-molecular-weight kininogen to bradykinin, a vasoactive and nociceptive peptide [7]. It can also 
cleave prothrombin, FXIII and TAFI, thus MASP-1 can modulate the function of the clotting and fibrinolytic 
systems [8-10]. Moreover, active MASP-1 (both in native form complexed with MBL and as recombinant, 
rMASP-1) is able to cleave protease activated receptors (PAR1, 2 and 4), and this generates a pro-
inflammatory signal in endothelial cells [11, 12]. Upon this stimulus, the endothelial cells produce IL-6 and 
IL-8 and thus, recruit neutrophil granulocytes [13]. 
Endothelial cells are vascular site specific regulators of several physiological processes [14, 15]. To interact 
with circulating blood cells, endothelial cells must utilize a wide range of adhesion molecules. These 
adhesion molecules can be classified according to their structure, subcellular localization, and function. 
Upon traumatic vascular injury, endothelial cells translocate their pre-formed P-selectin molecules onto the 
cell surface by degranulation occurring within a few minutes [16, 17]. P-selectin is the major lectin-type 
adhesion molecule of endothelial cells that interacts with platelets to ensure their adherence to the injured 
vessel wall. Inflammation induced by invading microorganisms or necrotic debris stimulates endothelial cells 
to modify the pattern of other adhesion molecules. Sialyl-Lewis X recognizing E-selectin is de novo 
synthesized by endothelial cells within hours of induction to enhance the initial adhesion and rolling of 
leukocytes on the endothelium [18, 19]. ICAM-1, a receptor of beta-2 integrins, is expressed on the surface 
of most endothelial cells (and of some leukocytes) at a low level; however, its expression is up-regulated 
within 12-24 hours in response to pro-inflammatory stimuli [20-22]. It participates in the transmigration of 
all types of leukocytes. VCAM-1 is another inflammatory adhesion molecule synthesized de novo, but only 
later (24 hours after) an appropriate stimulus. As a partner of VLA-4, it has a major role in the homing of T-
cells and monocytes, as well as subsets of neutrophils also use this adhesion molecule [23, 24]. ICAM-2 is an 
endothelial cell specific adhesion molecule. Although it is constitutively expressed on non-activated 
endothelial cells, its exact role is still not fully understood. ICAM-1 and ICAM-2 share their integrin ligands. 
However, the affinity spectrum of ICAMs towards different beta-2 integrins differ, and ICAM-2 does not 
induce outside-in signaling of integrin partner molecules [25, 26]. ICAM-2 expression decreases upon pro-
inflammatory stimuli [27]. 
To control leukocyte homing during inflammation, the production of cytokines and the expression of 
adhesion molecules are usually co-regulated in endothelial cells. We have previously described that 
rMASP-1 can induce IL-6 and IL-8 production in HUVECs, which is regulated predominantly by the p38-
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MAPK pathway [13]. Therefore, in this study we investigated how rMASP-1 can modify the pattern of 
P-selectin, E-selectin, ICAM-1, ICAM-2, and VCAM-1 adhesion molecules in endothelial cells. We also 
explored whether these changes can enhance the adherence between endothelial cells and neutrophil 
granulocytes. 
 
 
2. Material and methods 
 
2.1. Reagents 
 We used recombinant catalytic fragment of human MASP-1 (CCP1-CCP2-SP, hereinafter: 
rMASP-1). rMASP-1 was expressed in E. coli as described by Ambrus et al. [28], and prepared according to 
Dobó et al. [29]. Briefly, after dissolving inclusion bodies and refolding in glutathion/oxidized glutathion 
containing buffer for one month, rMASP-1 autoactivated during dialysis. Then sequential ion-exchange 
chromatographies of rMASP-1 were performed using anion-exchange (Source 30Q, GE Healthcare) and 
cation-exchange (SP Sepharose High Performance, GE Healthcare) columns. Purity was checked by PAGE, 
whereas enzymatic activity was measured by SLGR-AMC substrate cleaving assay. The rMASP-1 
preparations were free of bacterial contaminations, since its NFκB nuclear translocating activity could not be 
blocked with Polymyxin B or DNase, unlike control LPS and bacterial DNA. Furthermore, it could be 
inhibited by C1-Inhibitor as described previously [11-13]. The mouse anti-human P- and E-selectin, 
ICAM-1, ICAM-2 and VCAM-1 antibodies were purchased from Bender MedSystems (Affimetrix, Inc., San 
Diego). The FITC-conjugated mouse anti-human LFA-1 (CD11a/CD18), MAC-1 (CD11b/CD18), CD15 and 
CD49d antibodies were purchased from ImmunoTools (ImmunoTools GmbH, Germany). The Alexa 
Fluor®568-conjugated goat anti-mouse secondary antibody was purchased from Invitrogen (Invitrogen Co., 
Oregon, USA) and the horseradish-peroxidase (HRP) conjugated secondary antibody was obtained from 
Southern Biotech (SouthernBiotech, Birmingham, USA). The recombinant human E-selectin was supplied 
by Sino Biological (Sino Bilogical Inc., Bejing, P.R. China). All other reagents were purchased from 
Sigma-Aldrich, unless otherwise stated. 
 
2.2. Preparation and culturing of human umbilical vein endothelial cells (HUVECs) 
Cells were harvested from fresh umbilical cords obtained during normal deliveries of healthy 
neonates by collagenase digestion as described earlier [13, 30]. HUVECs were kept in gelatin-precoated 
flasks (Corning® Costar®) in MCDB131 medium (Life Technologies) completed with 5% heat–inactivated 
fetal calf serum (FCS), 2 ng/ml human recombinant epidermal growth factor (R&D Systems), 1 ng/ml 
human recombinant basic fibroblast growth factor (Sigma), 0.3% Insulin Transferrin Selenium (Life 
Technologies), 1% Chemically Defined Lipid Concentrate (Life Technologies), 1% Glutamax (Life 
Technologies), 1% Penicillin-Streptomycin antibiotics (Sigma), 5 µg/ml Ascorbic acid (Sigma), 250 nM 
Hydrocortisone (Sigma), 10 mM Hepes (Sigma), and 7.5 U/ml Heparin (this completed medium is 
hereinafter: Comp-MCDB). Each experiment was performed on at least three independent primary HUVEC 
cultures from different individuals before the 4th passage. The study was conducted in conformity with the 
WMA Declaration of Helsinki; its protocol was approved by the Semmelweis University Institutional 
Review Board (permission number: TUKEB64/2008), and all participants provided their written informed 
consent before inclusion. 
 
2.3. Culturing of the PLB-985 cell line, as a model for neutrophils 
PLB-985 cells were grown in RPMI-1640 medium (Life Technologies) supplemented with 10% 
FCS, 1% PEST, and 1% Glutamax. Then, the cells were differentiated into neutrophil-like cells for 6 days in 
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the presence of 1.25% dimethyl sulfoxide (DMSO) [31] (the differentiated PLB-985 cells are hereinafter 
referred to as dPLB-985 cells). Differentiation was checked by detecting CD11b, CD11a, CD15, CD43 and 
CD49d expression, and by ascertaining the capability of the cells to generate hydrogen-peroxide. 
 
2.4. Flow cytometry analysis 
4x106 PLB-985 or dPLB-985 cells were washed and resuspended in HBSS. To detect CD11a, 
CD11b, CD15, CD43 and CD49d expression, 5 µg of appropriate FITC conjugated antibodies, or the isotype 
control antibodies were added to the cell suspensions (5x105 cells in 50 µl PBS) and incubated for 30 min at 
4 ºC. The samples were then washed in 250 µl cold PBS containing 0.1% BSA, centrifuged and 
resuspended/fixed in PBS containing 2% formaldehyde for 15 minutes. Next, the samples were washed in 
250 µL PBS, centrifuged and resuspended in 300 µL PBS. Cell surface expression of adhesion molecules 
was monitored with a FACScalibur flow cytometer (Becton Dickinson, Franklin Lakes, NJ). No gates were 
used except FSC threshold avoiding debris and other microparticles. The FACS figures were plotted using 
Flowing Software 2.5 (www.flowingsoftware.com). 
 
2.5. Detection of hydrogen peroxide production 
An Amplex Ultra Red (Life Technologies) based fluorescence method was used [32] to quantitate 
the production of reactive oxygen species. In brief, 2x104 cells were activated with 100 nM phorbol 12-
myristate 13-acetate (PMA) or left untreated as controls. Then, fluorescence was recorded continuously for 
20 minutes, and expressed as arbitrary units. 
 
2.6. mRNA analysis 
Following pre-treatment by various methods, HUVECs were lysed and stored in TRI® reagent. Total 
RNA purification, reverse transcription and LightCycler® analysis were performed as described earlier [13, 
30]. The primers (Table 1) were designed with Primer3 (v. 0.4.0) designer from the NCBI database, and 
produced by Bio Basic Canada Inc.. β-actin and GAPDH gene-specific primers were used as internal 
controls. The purity and the size of the PCR products were checked by melting curve analysis, agarose gel-
electrophoresis, and sequencing. 
 
2.7. Visualization of adhesion molecules by immunofluorescence microscopy 
Confluent layers (104 cell/well) of HUVECs were cultured in 96-well plates (Corning® Costar®) for 
one day, then the cells were treated with 2 µM of rMASP-1, 300 nM thrombin, 50µM histamine or 10 ng/mL 
TNFalpha in 100 µl Comp-MCDB, or left untreated. After 5 minutes, 6 or 24 hours, the cells were fixed in 
1% formaldehyde for 15 min (for P-selectin), or in methanol-acetone (1:1) for 10 min (for other adhesion 
molecules). Then the cells were stained with primary anti-human antibodies as indicated (all antibodies were 
diluted 1:500), followed by Alexa Fluor®568-conjugated goat anti-mouse IgG (1:500), and Hoechst 33342 
(1:50000, Molecular Probes/Invitrogen). The preparations were read using an Olympus IX-81 fluorescence 
inverted microscope as described previously [13, 33]. 
 
2.8. Measurement of adhesion molecule expression by cell-based ELISA 
Confluent layers of HUVECs were cultured in 96-well plates for 24 hours. Then, HUVECs were 
treated with 0.2, 0.6, or 2 µM rMASP-1, 300 nM thrombin, or 10 ng/mL TNFalpha for 1, 3, 6, 10 or 24 
hours. The cells were fixed and stained with P-selectin, E-selectin, ICAM-1, ICAM-2, or VCAM-1 
antibodies for 60 minutes at room temperature. Then, HRP-conjugated goat anti-mouse antibody and 
3,3',5,5'-Tetra Methyl Benzidine (TMB) (Life Technologies) were used to measure the expression of 
adhesion molecules. 
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2.9. Measurement of PLB-985 and dPLB-985 cell adhesion to E-selectin coated plates 
96-well plates were coated with 0.2, 1, or 5 µg/mL recombinant human E-selectin (Sino Biological 
Inc.), or left uncoated for 1 hours at 37 ºC, and then blocked with PBS containing 2% BSA for 1 hour at 
37 ºC, in 5% CO2 atmosphere. PLB-985 or dPLB-985 cells were incubated in HBSS containing 2 µg/mL 
Oregon Green® 488 carboxylic acid diacetate succinimidyl ester (abbreviated as OG-488, Invitrogen) for 30 
min in the dark, at 37 ºC, in 5% CO2 atmosphere. Then, the cells were centrifuged, and resuspended in HBSS 
for 30 min. OG-488 labeled PLB-985 or dPLB-985 cell suspension was added to the E-selectin precoated 
wells (10000 cells/well), and incubated for 1 hour, at 37 ºC, in 5% CO2 atmosphere. Then, total number of 
dPLB-985 cells was determined with a fluorescence plate reader (Tecan Infinite® M1000 Pro), at 485 nm 
excitation and 525 nm emission wavelengths. Thereafter, the plate was washed twice vigorously with HBSS, 
and the fluorescence of bound cells was monitored again. The number of bound cells normalized with the 
initial number of cells was calculated after three independent measurements. 
 
2.10. Assessing dPLB-985 cell adhesion to HUVECs 
Confluent layers of HUVECs were cultured in 96-well plates and treated for 6 or 24 hours with 0.2, 
0.6, or 2 µM rMASP-1, 300 nM thrombin, or 10 ng/mL TNFalpha. Then, 2x104 OG-488 labeled dPLB-985 
cells/well were applied to the HUVECs, and incubated for 1 hour at 37 ºC, in 5% CO2 atmosphere. Total 
dPLB-985 cell number was monitored by fluorescence as described before. Thereafter, the plate was washed 
twice vigorously with HBSS using a multichannel pipettor, and the fluorescence of bound cells was 
monitored again. The ratio of bound to total cell numbers was calculated after three independent 
measurements. In some experiments, HUVECs were pre-incubated for 30 minutes with the following 
pathway inhibitors: 25 µM JNK inhibitor (SP600125), 2 µM p38-MAPK inhibitor (SB203580), 1 µM ERK 
1/2 inhibitor (U0126) or, 5 µM NfkappaB inhibitor (Bay-11 7082). Furthermore in some cases OG-488-
labeled dPLB-985 cells were pre-treated with 1 µg/mL recombinant E-selectin for 30 minutes, at 37 ºC, in 
5% CO2 atmosphere, before adding to the HUVECs, in order to assess the inhibition of adhesion. 
 
2.11. Measurement of the adhesion force between dPLB-985 cells and endothelial cells with a computer 
controlled micropipette method 
A computer controlled micropipette (CellSorter), mounted onto an inverted fluorescence microscope 
(Zeiss Axio Observer A1) [34, 35], was used to quantify the adhesion force between the variously pre-treated 
HUVECs and dPLB-985 cells. In brief, a confluent layer of HUVECs was cultured in a 35-mm tissue culture 
plastic Petri dish (Greiner) for one day. Then, they were treated/not treated with 2 µM of rMASP-1, 300 nM 
thrombin for 6 hours, or with 10 ng/mL TNFalpha for 24 hours. 105 OG-488 labeled dPLB-985 cells were 
placed into the Petri dish containing the endothelial cells, and incubated for 60 minutes at room temperature. 
Attached dPLB-985 cells were scanned and recognized using the CellSorter software. The adhesion force 
was measured with a glass micropipette with an inner diameter of 70 µm. The micropipette was 
automatically positioned to 100 selected cells (diameter ~13 µm) one by one, in order to try to pick them up 
(Fig. 5A). Repeating this cycle (i.e. the positioning and pick-up process) each time on the same path with an 
increased vacuum (expressed in kPa), the adhesion force of cells could be precisely measured. The number 
of the cells was counted before and after each cycle, and the ratio of adherent to originally selected cells was 
calculated. 
 
2.12. Statistical analysis 
Statistical analyses were performed using Student’s t-test, one-way ANOVA with Tukey’s post-test 
or a post-test for linear trends, or two-way ANOVA with Bonferroni post-test (GraphPad Prism 5.01 
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software, GraphPad, http://www.graphpad.com/). A p-value less than 0.05 was considered statistically 
significant. The data are presented as means ± SEM unless otherwise stated. 
 
 
3. Results 
 
3.1. Screening the mRNA expression of adhesion molecules 
Since pro-inflammatory adhesion molecules are usually synthesized de novo upon stimuli, we 
measured the mRNA levels of adhesion molecules by qPCR – except in the case of P-selectin, which is 
stored as a preformed protein in Weibel-Palade bodies. 
Confluent layers of HUVECs were treated with 2 µM rMASP-1 for 1, 2, 6 or 10 hours, to assess mRNA 
expression. rMASP-1 greatly up-regulated the mRNA expression of E-selectin and VCAM-1 in endothelial 
cells, although the increment was somewhat less in the latter. Maximum effect was observed between 2 and 
6 hours and then, the expression of both adhesion molecules declined. The level of ICAM-2 mRNA 
decreased until the end of the measurement, whereas the expression of ICAM-1 mRNA did not change upon 
rMASP-1 stimulation (Fig. 1A). 
 
3.2. The effect of rMASP-1 on the expression of cell adhesion molecules 
The altered expression of these adhesion molecules indicates the pro-inflammatory changes 
occurring in endothelial cells. Moreover, the effects of known endothelial cell activators (such as thrombin, 
TNFalpha or histamine) are well characterized with regard to adhesion molecules. 
Thrombin and histamine induced prompt P-selectin expression at 5 minutes, and reuptake by endothelial 
cells within 60 minutes; however, rMASP-1 failed to increase P-selectin expression (Fig. 1, B and C). 
Fluorescence microscopy showed that rMASP-1, thrombin, and TNFalpha induced the expression of 
E-selectin at 6 hours (Fig. 1B). Using cell-based ELISA, we demonstrated that the effect of rMASP-1 on E-
selectin expression declined by 24 hours, similar to that of thrombin, but unlike to that of TNFalpha (Fig. 
1C). rMASP-1 did not modify the expression of ICAM-1 at any time (Fig. 1, B and C). By contrast, both 
thrombin and TNFalpha elevated the level of ICAM-1, although with different kinetics (Fig. 1C). rMASP-1, 
thrombin, and TNFalpha all reduced ICAM-2 expression at 6 hours, and even further at 24 hours (Fig. 1, B 
and C). Interestingly, although rMASP-1 significantly induced the expression of VCAM-1 mRNA, it had no 
effect on VCAM-1 protein level (Fig. 1, B and C). Thrombin behaved similar to rMASP-1 in respect of 
VCAM-1 protein expression; however, TNFalpha induced VCAM-1 at 6 hours, and this effect was even 
more pronounced at 24 hours (Fig. 1, B and C).  
 
3.3. rMASP-1 dose dependence and the kinetics of E-selectin and ICAM-2 expression 
It is known that the expression kinetics of various adhesion molecules depends on the inherent 
properties of the adhesion molecule itself, and on those of the activator. The difference in expression kinetics 
can regulate selective cell adhesion. To assess the influence of rMASP-1 kinetics on the expression of 
adhesion molecules at protein level, HUVECs were treated with 2µM rMASP-1 for 1, 3, 6, 10 and 24 hours 
and then, cell-based ELISA was performed. Similar to the kinetics seen at mRNA level (Fig. 1A), the protein 
expression of E-selectin was increased as early as at 3 hours, but the maximum effect was observed at 6 
hours. E-selectin expression declined until 24 hours post treatment (Fig. 2A). In contrast to E-selectin, 
ICAM-2 level was lower at 3 hours than that of the untreated control, and decreased continuously until 24 
hours (Fig. 2B). Then, at the times of maximum rMASP-1 effect, we assessed dose dependence. We found 
that treatment with rMASP-1 induced E-selectin and reduced ICAM-2 expression in a dose-dependent 
manner (Fig. 2, C and D). 
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3.4. Measurement of adhesion between dPLB-985 cells and endothelial cells 
To clarify the biological importance of the previously described alterations of endothelial adhesion 
molecules, we assessed whether these molecules can bind to neutrophil granulocytes. In these adhesion 
measurements, we used the acute myeloid leukemia cell line PLB-985, differentiated with DMSO toward 
neutrophil-like cells (dPLB-985). To verify the effectiveness of the differentiation of dPLB-985 cells, we 
tested the cell surface expression of adhesion molecules, and the generation of reactive oxygen species. 
dPLB-985 cells expressed CD11a and CD11b in increased quantities, and reduced amount of CD49d 
compared to non-differentiated PLB-985 cells. The expression of CD15 and CD43 did not change 
significantly (Fig. 3A). Moreover, dPLB-985 cells, unlike their ancestors, generated reactive oxygen species 
in response to 100 nM PMA, as measured by H2O2 production (Fig. 3B).  
To test the adhesive capacity of dPLB-985 cells to E-selectin, microwell plates were coated with 0.2, 
1, or 5 µg/mL recombinant E-selectin, or left untreated. Then, OG-488-labeled PLB-985 or dPLB-985 cells 
were added, incubated for 1 hour, washed, and the number of adherent cells was calculated. The adhesion of 
dPLB-985 cells to the coated plate was dose–dependent, and treatment with E-selectin in a concentration as 
low as 5 µg/mL resulted in significant adhesion compared to the uncoated controls. We did not observe 
similar dose-dependent adhesion of non-differentiated PLB cells to E-selectin coated plates (Fig. 4A). 
Since we demonstrated that rMASP-1 treatment induces E-selectin expression in HUVECs, and dPLB-985 
cells can adhere to recombinant E-selectin, we assessed the adherence between dPLB-985 cells and 
HUVECs treated with rMASP-1. To this end, HUVECs were treated with 0.2, 0.6, or 2 µM rMASP-1, 
300 nM thrombin or 10 ng/mL TNFalpha for 6 or 24 hours, or left untreated. Then OG-488 labeled 
dPLB-985 cells were applied onto the HUVECs and incubated for 1 hour. The number of adhered dPLB-985 
cells was measured by fluorescence, and normalized with baseline total cell number. We observed that 
rMASP-1 treatment increased dPLB-985 cell adhesion to HUVECs in a dose dependent manner at 6 hours, 
but not at 24 hours (Fig. 4B). Both the kinetics and the volume of this effect were similar for rMASP-1 and 
for thrombin. In contrast, TNFalpha induced enhanced adhesion to HUVECs at 6 hours, but adherence was 
even greater by 24 hours (Fig. 4C). The adhesion between dPLB-985 cells and rMASP-1-induced HUVECs 
could be reduced to the level of untreated HUVECs by pre-incubating the dPLB-985 cells with 1 µg/mL 
soluble recombinant E-selectin for 30 minutes (Fig. 4D). 
Expression of adhesion molecules can be triggered through various signaling pathways. We reported that 
most of these pathways can also be activated by rMASP-1 in HUVECs [13]. We used commercially 
available signaling pathway inhibitors to identify the most important pathways required for the E-selectin 
mediated adhesion between dPLB-985 cells and rMASP-1-induced HUVECs. HUVECs had been pre-
incubated with the inhibitors for 30 minutes and then, treated with 2 µM rMASP-1 for 6 hours. Only the p38-
MAPK inhibitor was able to block this adhesion, whereas JNK, NFkappaB, and ERK 1/2 pathway inhibitors 
had no blocking effect (Fig. 4D). 
We used a computer controlled micropipette method to quantify the adhesion force between dPLB-
985 cells and rMASP-1-treated HUVECs [34, 35]. HUVECs were induced with 2 µM of rMASP-1, 300 nM 
thrombin for 6 hours, or 10 ng/mL TNFalpha for 24 hours or left untreated. Then, OG-488-labeled 
dPLB-985 cells were added and incubated for 1 hour. The attached dPLB-985 cells were probed (i.e., by 
trying to pick them up) with the automated micropipette. The hydrodynamic lifting force, acting on the 
targeted single cells, was increased in each subsequent cycle of the measurement (Fig. 5A). More dPLB-985 
cells stayed attached to rMASP-1-treated endothelial cells than to non-treated controls at higher detaching 
forces. We observed the same effect after thrombin treatment (Fig. 5B). Induction with TNFalpha for 24 
hours, used as positive control, was the most potent in enhancing adhesion (by 4.28-fold, ±1.63, p<0.01 at 
19.2 kPa vacuum). 
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4. Discussion 
 
Infection and tissue damage initiate pro-inflammatory activation of the endothelium. This 
modification of the endothelial cell phenotype includes altered cytokine production and adhesion molecule 
pattern. In the present study, we found that rMASP-1 treatment changed the adhesion molecule pattern, 
reduced the expression of ICAM-2, and increased that of E-selectin, whereas ICAM-1, VCAM-1 and P-
selectin did not change. Furthermore, these alterations increased the adherence between neutrophil model 
cells (dPLB-985) and endothelial cells. 
The migration of different leukocyte subsets depends, in the first place, on the pattern of chemokines and 
adhesion molecules produced by the endothelium. Earlier, we have demonstrated that rMASP-1 induces 
pro-inflammatory processes in endothelial cells. In particular, they activate Ca2+, NFκB, p38-MAPK, JNK, 
and CREB signaling pathways by cleaving PARs [11, 13]. Moreover, rMASP-1-stimulated endothelial cells 
produce IL-6 and IL-8, as well as recruit neutrophil granulocytes [13]. Therefore, our previous and current 
results together imply a novel, endothelial cell mediated pro-inflammatory role for rMASP-1. 
Although MASP-1 is the most abundant protease of the lectin pathway, its isolation from human serum is a 
low-yield process, and the produced protein is prone to degradation during the purification. The catalytic 
region of MASP-1, containing the CCP1, CCP2 and SP domains, is enzymatically equivalent to the full-
length molecule. Structural studies showed that only the catalytic region is accessible to the substrates 
present in MBL-MASP-1 complexes, since only the CCP1-CCP2-SP domains protrude from the plane of 
MBL [36]. Previously, we demonstrated equivalent cellular effects of the serum purified MBL-MASP 
complex, and of the recombinant catalytic fragment of human MASP-1. Serum purified MASP-1 and 
rMASP-1 used in equimolar concentration induced the same intensity of Ca-mobilization, and both could be 
completely blocked with C1-inhibitor [12]. In the current study, we observed significant effects of MASP-1 
on adhesion molecules and adhesion between 0.2 and 2 µM, which is higher than the plasma concentration 
of MASP-1 (~143 nM). However, at the site of injury and/or infection, MASP-1 may be trapped via the 
pattern recognition of MBL and ficolins, thus the local concentration may be much higher than its plasma 
concentration. 
P-selectin, one of the best-characterized components of Weibel-Palade bodies [16], is released rapidly in 
response to among others thrombin and histamine by G-protein coupled PARs [37], and by histamine H1 
receptors [38], respectively. Although it plays a role in the inflammatory response by mediating the rolling of 
leukocytes on the endothelium [38], the most critical function of P-selectin is to facilitate platelet 
aggregation at the sites of vascular injury [39]. In contrast to P-selectin, E-selectin is an endothelial cell-
specific adhesion molecule; it recognizes sugar motifs containing sialyl-Lewis X on leukocytes, and has an 
important role in the initial step of the endothelium/leukocyte adhesion – leukocyte rolling [40, 41]. E-
selectin is not detectable on the surface of normally functioning endothelial cells and it is also absent from 
their cytoplasm; however, upon pro-inflammatory stimuli (e.g. by TNFalpha, LPS, IL-1β), it is synthesized 
de novo within hours [42]. Our results indicate that rMASP-1 alone possibly cannot influence the endothelial 
cell/platelet interaction, but it may regulate the rolling of leukocytes on endothelial cells via the upregulation 
of E-selectin.  
ICAM-1 and ICAM-2 are members of the Ig superfamily; they bind β2-integrins (CD11a/CD18, 
CD11b/CD18 and CD11c/CD18) with different affinity [25]. ICAM-1 is expressed at a low level on 
endothelial cells with a non-inflammatory phenotype, as well as on different leukocyte subsets, and their 
expression is induced – similar to E-selectin – by pro-inflammatory factors [33]. Unlike ICAM-1, ICAM-2 is 
specific to endothelial cells, as well as it is constitutively and strongly expressed on normally functioning 
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cells. Upon pro-inflammatory stimulation, the cells reduce its expression in parallel with the elevation of 
ICAM-1 levels. Further, their outside-in signaling is different, as the crosslinking of ICAM-1 induces actin 
reorganization via RhoA. Thus, it participates in the cellular movements of endothelial cells during leukocyte 
transmigration, whereas ICAM-2 lacks this function [26]. VCAM-1, another endothelial cell-specific 
adhesion molecule expressed upon pro-inflammatory stimuli, reaches its maximum 24 hours after activation; 
it is a ligand for VLA-4 and other β1-integrins [23]. VCAM-1 is required for the transmigration of T cells 
and monocytes; however, neutrophils may also use the VLA-4/VCAM-1 adhesion for homing [43]. rMASP-
1 did not induce the expression of ICAM-1 nor VCAM-1 and thus, it may not have a direct influence on the 
firm contact and on the transmigration of the leukocytes through the endothelium. However, by decreasing 
ICAM-2, it biases the ICAM-1 to ICAM-2 ratio, and this may potentiate transmigration upon other 
synergistic pro-inflammatory stimuli (such as by LPS, TNFalpha or C5a). Moreover, the elevation of 
VCAM-1 expression only at mRNA level also suggests a potential for synergism. The discrepancy between 
mRNA and protein levels of VCAM-1 is not unknown [44, 45]. MicroRNAs may block translation of 
VCAM-1 without degradation of mRNA or post-translational degradation can decrease the protein level, 
however, the exploration of the molecular mechanism is beyond the scope of this study. 
rMASP-1 induced a unique pattern and kinetics of adhesion molecules that differs from those induced by 
TNFalpha and thrombin. The dissimilarity between rMASP-1 and TNFalpha is not surprising, because 
TNFR strongly activates NFκB, p38-MAPK and JNK signaling pathways [33]. Further, it does not trigger 
Ca-mobilization, whereas PARs cleaved by rMASP-1 induce Ca-mobilization, JNK and p38-MAPK 
phosphorylation, but only weak NFκB nuclear translocation [11, 13]. More interestingly, the rMASP-1- and 
thrombin-induced patterns of adhesion molecules were also different. The expression of P-selectin and of 
ICAM-1 was enhanced by thrombin, but not by rMASP-1 – this can be explained by the different utilization 
of PARs. While thrombin cleaves PAR-1 and – to a lesser extent – PAR-4, rMASP-1 is most effective in 
cleaving PAR-4, followed by PAR-2 and PAR-1 [11]. If we consider the expression profile of different 
PARs on endothelial cells (PAR-2 expression is the highest, followed by PAR-1, and – to a much less extent 
– by PAR-4) [11], only partial overlap can be supposed between thrombin and rMASP-1 signaling. 
Differential signal transduction by the various PARs is well known and in support of our findings [46]. Since 
we have previously found that in the case of rMASP-1, the cytokine production was regulated predominantly 
by p38-MAPK pathway [13], it is not unexpected that only the p38-MAPK inhibitor was able to block 
adhesion between dPLB-985 cells and rMASP-1-induced HUVECs. 
Since rMASP-1-treated HUVECs produce IL-8 but not MCP-1 [13], and as we have found an elevated level 
of E-selectin, but not of ICAM-1 or of VCAM-1, we propose that rMASP-1 induced an endothelial cell 
phenotype most suitable for the adhesion of neutrophils. Nevertheless, we could not exclude the possibility 
that other adhesion molecules than E-selectin, which were not measured in this study, are also involved in 
the increased adhesion. HUVECs from different donors exhibit significant heterogeneity [47]. To reduce 
further variances in our experiments, we used a DMSO-differentiated PLB-985 cell line – devoid of the 
heterogeneity of primary cells, which is a well-known and suitable cellular model to study the functional 
responses of neutrophils [31, 48]. Furthermore, dPLB-985 could bind to E-selectin, whereas non-
differentiated PLB-985 could not, and this supports that it could be a suitable model for the assessment of 
adhesion. The pattern of dPLB-985 binding to HUVECs subjected to different pre-treatments was rather 
similar to that of the expression of E-selectin. rMASP-1 and thrombin enhanced adhesion, and elevated the 
E-selectin level only 6 hours after treatment – TNFalpha was superior in regard of both parameters, and at 
any times after induction. The possible role of E-selectin in this static model of dPLB-985 binding to 
HUVECs is further supported by the inhibition of adhesion by soluble E-selectin. To assess the adhesion 
force between rMASP-1-treated HUVECs and dPLB-985 cells, we utilized the recently introduced computer 
controlled micropipette method [34, 35]. Previously, it was applied to measure the adherence of 
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macrophages and dendritic cells to fibrinogen, and to poly-L-Lys-graft-PEG. The adhesion force was in the 
same order of magnitude [35] as we found in the case of HUVECs/dPLB-985 cells. Our present data suggest 
that rMASP-1 induced high adhesion forces between dPLB-985 cells and HUVECs. The greatest difference 
– compared to untreated HUVECs – was measured at the highest detaching forces. This means that the 
number of firmly adherent cells increased significantly. 
The complement system is a powerful defense mechanism for eliminating pathogens and necrotic debris. 
However, one of its main functions, the opsonization of unwanted particles, requires the presence of 
phagocytic cells. We found that complement MASP-1 can enhance the adhesion between neutrophils and 
endothelial cells in a direct fashion, and may thereby accelerate the recruitment of neutrophils at the scene of 
infection or tissue damage. This is in agreement also with our previous finding that MASP-1 increases the 
production of pro-inflammatory cytokines, such as of IL-6 and IL-8. Enhanced chemotaxis and adhesion 
may boost neutrophil functions; however, this hypothesis should be tested by further research. 
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Table 1 
Primers for the analysis of mRNAs of the adhesion molecules. 
 
forward: 5’-tcaagtgtgagcaaattgtgaac-3’ E-
selectin reverse: 5’-attctccagaggacatacactgc-3’ 
forward: 5’-acagtcacctatggcaacgac-3’ 
ICAM-1 
reverse: 5’-gtcactgtctgcagtgtctcct-3’ 
forward: 5’-acagccacattcaacagcac-3’ 
ICAM-2 
reverse: 5’-agatgtcacgaacagggacag-3’ 
forward: 5’-tgaccttcatccctaccattga-3’ VCAM-1 
reverse: 5’-gcatgtcatattcacagaactgc-3’ 
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Fig. 1. 
 
 
Fig. 1. Adhesion molecule patterns induced by rMASP-1 on HUVECs. (A) HUVECs were treated with 2 
µM MASP-1 for 1, 2, 6, or 10 hours. Then, the cells were lysed and stored in TRI-reagent, total mRNA was 
purified, and qPCR performed. Values of the quantities of the adhesion molecule mRNAs in three 
independent experiments were normalized for that of GAPDH, used as internal control. P-selectin was not 
analyzed by qPCR, because of its instant secretion from pre-formed granules. (B) HUVECs were treated 
with 2 µM MASP-1, 300 nM thrombin, 50 µM histamine, or 10 ng/mL TNFα for 5 minutes (P-selectin), or 
for 6 hours (in the case of all other adhesion molecules). Then, cells were fixed and stained with mouse 
monoclonal anti-adhesion molecule antibodies, followed by goat-anti-mouse Alexa 568 (red) and Hoechst 
33342 (blue) as nuclear staining. Each subfigure of panel B is a representative photo of three independent 
experiments. (C) HUVECs were treated in 96-well plates as described in panel (B), and cellular ELISA was 
performed. The values represent the ratio of the optical density of treated vs. non-treated wells, and the 
difference was analyzed by ANOVA with Tukey's post-test. Dotted lines represent the untreated control 
levels. The values were calculated as the mean (+/-SEM) of three independent experiments. *: p<0.05, **: 
p<0.01, ***: p<0.001. 
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Fig. 2. 
 
 
 
Fig. 2. Dose- and time- dependence of E-selectin and ICAM-2 expression induced by rMASP-1. 
HUVECs were treated with 2 µM of rMASP-1 for 1, 3, 6, 10, and 24 hours (A and B), or with 0, 0,2, 0,6, 
2 µM MASP-1 for 6 hours (C) and 24 hours (D). Then, relative expression (compared to untreated controls 
of E-selectin and ICAM-2) was measured by cell-based ELISA. Dotted lines represent the untreated control 
levels. The values were calculated as the mean (+/-SEM) of three independent experiments. One-way 
ANOVA has been performed for each subfigure. In the case of kinetic measurements p<0.01 for A and 
p<0.05 for B, and of dose-dependence experiments, ANOVA (p<0.05 for C and p<0.001 for D) was 
supplemented with post-test for linear trend (r=0.55, p<0.01 for C and r=-0.69, p<0.001 for D). 
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Fig. 3. 
 
 
 
Fig. 3. The effects of PLB-985 cell differentiation on adhesion molecule pattern and hydrogen 
peroxyde generation. (A) PLB-985 cells or DMSO-differentiated PLB-985 cells were suspended in HBSS. 
Specific mouse antibodies or isotype controls were added to the cell suspensions and incubated for 30 min, at 
4 ºC. After washing, samples were fixed in 2% formaldehyde for 15 minutes, and suspended in PBS for flow 
cytometry analysis. 104 cells were measured in each sample. RMF: Ratio of geometric mean fluorescence 
intensity values of labeled cells and of respective isotype controls. (B) HRP and Amplex Ultra Red 
fluorescence substrate was added to PLB-985 or dPLB-985 cells, which were then activated with 100 nM 
PMA or left untreated. Fluorescence was recorded every 10 seconds for 20 minutes, and expressed as 
arbitrary units. One representative experiment out of three is shown. 
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Fig. 4. 
 
 
 
Fig. 4. The adhesion of dPLB-985 cells to E-selectin coated plates or to MASP-1-treated endothelial 
cells. (A) After 96-well plates had been pre-coated with 0, 0.2, 1, or 5 µg/mL E-selectin, OG-488-labeled 
PLB-985 or dPLB-985 cells were added to the wells and incubated for 1 hour, at 37 ºC, in 5% CO2 
atmosphere. Then, the fluorescence of bound cells was detected after washing with HBSS. The number of 
bound cells in three independent measurements was calculated. (B, C) HUVECs were treated with 0, 0.2, 
0.6, and 2 µM MASP-1 for 6 and 24 hours (B), with 2µM of rMASP-1, 300 nM thrombin, or 10 ng/mL 
TNFalpha – or left untreated – for 6, and 24 hours (C), and adhesion was measured as in panel A. (D) 
Adhesion of OG-488-labeled dPLB-985 to HUVECs treated with 2 µM MASP-1 for 6 hours was inhibited 
either by pre-incubation of HUVECs with p38-MAPK, JNK, NFκB, or ERK 1/2 inhibitor for 30 minutes or 
by pre-incubation of dPLB-985 with soluble recombinant E-selectin for 30 minutes. Then adhesion was 
assessed as described above in panel A, and the inhibition is shown as the percentage of the MASP-1 
induced adhesion. The values were calculated as the mean (+/-SEM) of at least three independent 
experiments. Two-way ANOVA was used for panel A, whereas one-way ANOVA has been performed for 
panel B, C and D. Dotted lines represent the untreated control levels. *: p<0.05, **: p<0.01, ***: p<0.001. 
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Fig. 5. 
 
 
 
Fig. 5. Adhesion force measurement between cells using an automated micropipette. (A) Schematic 
representation of the hydrodynamic adhesion force measurement. OG-488 labeled dPLB-985 cells attached 
to the confluent layer of HUVECs were scanned and recognized by software in the microscopic images 
captured on a motorized inverted microscope. A glass micropipette was automatically positioned to each 
detected cell one by one. Cell adhesion was probed by the application of a precisely controlled fluid flow 
through the micropipette. (B) Adhesion force between dPLB-985 cells and MASP-1-treated endothelial cells.  
HUVECs were treated in Petri dishes with 2 µM of rMASP-1, or 300 nM thrombin for 6 hours, or with 
10 ng/mL TNFalpha for 24 hours, or left untreated. Then, OG-488-labeled dPLB-985 cells were seeded onto 
the HUVECs (subjected to different pre-treatments) for 1 hour. The adhesion force between dPLB-985 cells 
and HUVECs was tested by the computer controlled micropipette method. The vacuum applied (expressed in 
kPa) was proportional to the hydrodynamic lifting force acting on the targeted single cells. Significant 
deviation from the untreated values in the high-vacuum range of the plot means that the ratio of cells 
exhibiting firm adhesion was increased by treatment. The values were calculated as the ratio of bound cell 
number of treated and non treated samples at each vacuum pressure points, and shown as the mean (+/-SEM) 
of at least three independent experiments. One-way ANOVA has been performed for panel B. Dotted lines 
represent the untreated control levels. *: p<0.05, **: p<0.01. 
 
